MSLN and carcinoma: It is possible that 22A31 interrupts the heterotypic interaction between ERC/mesothelin and other molecules such as CA125/MUC16 on the surface of tumor cells or adjacent stromal cells, leading to the suppression of proliferative activities of carcinoma cells.